DXCM CLASS ACTION LAWSUIT: A Securities Fraud Class Action has been filed against DexCom, Inc. – Investors are Notified to Contact BFA Law to Potentially Recover Investment Losses

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in DexCom, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/dexcom-inc.

Investors have until December 26, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in DexCom securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Prime v. DexCom, Inc., et al., No. 1:25-cv-08912.

Why Was DexCom Sued Under the Federal Securities Laws?

DexCom manufactures continuous glucose monitoring (“CGM”) systems, including the Dexcom G6 and its flagship Dexcom G7.

During the relevant period, DexCom touted the reliability and accuracy of the G7, claiming it was “the most accurate CGM” on the market. The company also told investors that enhancements it made to the G7 were “making it even better” and “enrich[ing] the experiences” of its customers.

As alleged, in truth, DexCom made unauthorized design changes to the G6 and G7, which reduced the accuracy of the devices and exposed customers to potentially life-threatening health risks, and the company ignored safety issues to keep costs down.

The Stock Declines as the Truth Is Revealed

Between March and October 2025, DexCom faced multiple setbacks tied to G6 and G7 quality issues, each triggering significant stock declines. On March 7, 2025, the company disclosed it received an FDA warning letter regarding manufacturing and quality control concerns, which caused DexCom stock to decline $7.12 per share, or more than 9%.

When the FDA published the letter on March 25, 2025, revealing DexCom had modified the G6 and G7 without approval, and that the modifications reduced the accuracy of the products and put customers’ health at risk, DexCom stock fell another $3.19 per share, or more than 4%, over two trading days.

Then, on September 18, Hunterbrook published “Dexcom’s Fatal Flaws,” a report based on FDA documents, and the accounts of doctors, patients, and DexCom employees, which revealed “G7 users have been hospitalized and died” and that “Dexcom staff say corporate culture put margins over safety.” The Hunterbrook report caused a nearly 12% drop of $8.99 per share over two trading days.

Click here for more information: https://www.bfalaw.com/cases/dexcom-inc.

What Can You Do?

If you invested in DexCom you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/dexcom-inc

Or contact:
Ross Shikowitz
ross@bfalaw.com
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/dexcom-inc

Attorney advertising. Past results do not guarantee future outcomes.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.